Esperion Therapeutics Cash Flow - Quarterly (NASDAQ:ESPR)

Add to My Stocks
$39.01 $0.04 (0.1%) ESPR stock closing price Mar 22, 2017 (Closing)

For analyzing any company like Esperion Therapeutics from an investment perspective, its important to check the cash flow statement. While its important to look at the Esperion Therapeutics debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Esperion Therapeutics revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. This statement can tell if a company is running out of money while still being profitable and is useful in Esperion Therapeutics stock analysis. Esperion Therapeutics had a negative net income cash flow of $-74.97M for the latest quarter. This report is very useful in measuring the short term viability of a company. Esperion Therapeutics has a negative cash and cash equivalents change of $-39.17M. View details of Esperion Therapeutics cash flows for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Esperion Therapeutics Net Income Cash Flow
-74.97M-46.02M-28.62M-14.58M-49.78M-36.66M-23.86M-11.46M-36.37M-26.91M
Depreciation Depletion Amortization Cash-Flow1.31M0.99M0.64M0.33M0.94M0.61M0.32M0.1M0.39M0.28M
Net Increase (Decrease) in Assets Liabilities9.98M1.23M2.18M-0.1M-2.08M-1.99M0.69M0.02M0.25M0.16M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net15.95M12.38M8.67M4.55M12.77M8.33M4.97M2.07M3.71M2.65M
Esperion Therapeutics Net Cash from (used by) Operating Activities
-47.73M-31.41M-17.11M-9.8M-38.15M-29.7M-17.87M-9.26M-32.02M-23.81M
Increase (Decrease) in Prop Plant And Equipment-0.09M-0.01M-0.01M--0.3M-0.08M-0.01M-0.01M-0.86M-0.84M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments10.21M2.37M-10.69M-29.96M-159.76M-165.32M-128.13M-57.54M-35.73M3.12M
Other Cash Inflow (Outflow) from Investment Activities----------
Esperion Therapeutics Net Cash from (used by) Invesment Activities
10.11M2.36M-10.7M-29.96M-160.06M-165.41M-128.15M-57.54M-36.59M2.28M
Issuance (Purchase) of Equity Shares0.04M0.04M0.03M0.02M191.16M191.15M190.78M190.41M92.28M0.38M
Issuance (Repayment) of Debt Securities-1.6M-1.19M-0.78M-0.39M-0.63M-0.25M--4.83M4.83M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Esperion Therapeutics Net Cash from (used by) Financing Activities
-1.55M-1.14M-0.75M-0.36M190.52M190.9M190.78M190.41M97.12M5.22M
Effect of Exchange Rate Changes on Cash----------
Esperion Therapeutics Net Change in Cash & Cash Equivalents
-39.17M-30.19M-28.56M-40.12M-7.7M-4.21M44.74M123.6M28.5M-16.3M
Cash & Equivalents at Beginning of Year77.33M85.03M56.53M6.51M1.57M3.41M----
Cash & Equivalents at Year End38.16M47.14M48.76M37.2M77.33M80.82M129.78M208.64M85.03M40.23M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Cash flow for another ticker

Esperion Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Esperion Therapeutics stock price history.
The statement of cash flows can be categorized into three main sections:
  • Net Change in Cash and Cash Equivalents: Esperion Therapeutics cash reduced QoQ to $-74.97M, meaning the company is unable to meet its expenditure and grow cash which will also eventually reflect in the Esperion Therapeutics stock price movement.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-47.73M for ESPR.
  • Cash Flow from investment activities: Esperion Therapeutics generated $7.75M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $-1.55M for Esperion Therapeutics. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.
.